Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Recce Pharmaceuticals Ltd. ( (AU:RCE) ) has shared an update.
Recce Pharmaceuticals has been awarded an Advanced Overseas Finding for up to A$85 million by the Australian Government, which extends the 43.5% R&D Tax Incentive to the company’s overseas R&D activities for three years. This decision supports Recce’s global anti-infective programs, including a Phase 3 clinical trial for Diabetic Foot Infection in Indonesia, and highlights the company’s efforts in addressing antibiotic resistance.
The most recent analyst rating on (AU:RCE) stock is a Hold with a A$0.52 price target. To see the full list of analyst forecasts on Recce Pharmaceuticals Ltd. stock, see the AU:RCE Stock Forecast page.
More about Recce Pharmaceuticals Ltd.
Recce Pharmaceuticals Limited is a leading developer in the pharmaceutical industry, focusing on a new class of synthetic anti-infectives. The company is engaged in research and development of synthetic antibiotics, with a market focus on combating infectious diseases.
Average Trading Volume: 141,986
Technical Sentiment Signal: Buy
Current Market Cap: A$167.7M
See more data about RCE stock on TipRanks’ Stock Analysis page.